Facebook
Twitter
Telegram
Report an ErrorX4 Pharmaceuticals Balance Sheet 2011-2024 | XFOR
Annual Balance Sheet X4 Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-43.5 M | -88.2 M | -47.6 M | -44.7 M | -103 M | -22.9 M | -64.6 M | 12.3 M | 435 K | - | - | - | - |
Long Term Debt |
54.6 M | 32.3 M | 33.1 M | 33.2 M | 20.1 M | 7.89 M | 9.92 M | 10.1 M | 4.7 M | - | - | - | - |
Long Term Debt Current |
1.1 M | 1.2 M | 1.08 M | 786 K | 898 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 22 M | 9.01 M | 11.9 M | 52.1 M | 37.2 M | - | - | - | - |
Total Current Liabilities |
22.9 M | 22.3 M | 14 M | 11.9 M | 9.45 M | 5.4 M | - | - | - | - | - | - | - |
Total Liabilities |
96.2 M | 81.5 M | 52.8 M | 50.1 M | 31.5 M | 14.4 M | 22.5 M | 64.2 M | 43.8 M | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | 737 K | 694 K | 504 K | 430 K | - | - | - | - |
Retained Earnings |
-478 M | -377 M | -283 M | - | -132 M | -135 M | -92.3 M | -58.4 M | -35.4 M | - | - | - | - |
Total Assets |
147 M | 156 M | 117 M | 123 M | 161 M | 36 M | 81.3 M | 7.6 M | 9.51 M | - | - | - | - |
Cash and Cash Equivalents |
99.2 M | 122 M | 81.8 M | 78.7 M | 126 M | 8.13 M | 26.7 M | 3.43 M | - | - | - | - | - |
Book Value |
51.1 M | 74.1 M | 64.4 M | 72.8 M | 129 M | 21.6 M | 58.7 M | -56.6 M | -34.3 M | - | - | - | - |
Total Shareholders Equity |
51.1 M | 74.1 M | 64.4 M | 72.8 M | 129 M | -77.1 M | -44.5 M | -56.6 M | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet X4 Pharmaceuticals
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
55 M | 55 M | 55 M | 32.5 M | 32.5 M | 32.5 M | 32.5 M | - | 32.5 M | 32.5 M | 32.5 M | 32.5 M | 32.5 M | 33.2 M | 32.5 M | 32.5 M | 32.5 M | 20 M | 20 M | 22.2 M | 14.2 M | 8.31 M | 8.31 M | 8.31 M | 8.31 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
111 M | 96.2 M | 106 M | 106 M | 72.7 M | 81.5 M | 51.6 M | - | 49.9 M | 52.8 M | 51.8 M | 52.4 M | 54.1 M | 50.1 M | 50.1 M | 50.1 M | 50.1 M | 31.5 M | 31.5 M | 31.5 M | 31.5 M | 21.6 M | 21.6 M | 21.6 M | 21.6 M | 22.5 M | 22.5 M | 22.5 M | 22.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-530 M | -478 M | -459 M | -456 M | -401 M | -377 M | -348 M | - | -305 M | -283 M | -253 M | -232 M | -213 M | -194 M | -194 M | -194 M | -194 M | -132 M | -132 M | -132 M | -132 M | -79.2 M | -79.2 M | -79.2 M | -79.2 M | -92.3 M | -92.3 M | -92.3 M | -92.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
112 M | 147 M | 173 M | 173 M | 124 M | 156 M | 113 M | - | 99.6 M | 117 M | 121 M | 142 M | 161 M | 123 M | 123 M | 123 M | 123 M | 161 M | 161 M | 161 M | 161 M | 9.94 M | 9.94 M | 9.94 M | 9.94 M | 81.3 M | 81.3 M | 81.3 M | 81.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
60.5 M | 99.2 M | 132 M | 136 M | 94.4 M | 122 M | 81.1 M | 48.7 M | 67.7 M | 81.8 M | 77.7 M | 95.2 M | 115 M | 78.7 M | 78.7 M | 78.7 M | 78.7 M | 126 M | 126 M | 126 M | 126 M | 8.13 M | 8.13 M | 8.13 M | 8.13 M | 26.7 M | 76.8 M | 76.8 M | 76.8 M | 15.2 M | - | - | - | 7.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
1.04 M | 51.1 M | 67.6 M | 67.5 M | 51.7 M | 74.1 M | 61.8 M | - | 49.7 M | 64.4 M | 68.7 M | 89.2 M | 107 M | 72.8 M | 72.8 M | 72.8 M | 72.8 M | 129 M | 129 M | 129 M | 129 M | -11.7 M | -11.7 M | -11.7 M | -11.7 M | 58.7 M | 58.7 M | 58.7 M | 58.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
1.04 M | 51.1 M | 67.6 M | 67.5 M | 51.7 M | 74.1 M | 61.8 M | 30.1 M | 49.7 M | 64.4 M | 68.7 M | 87.3 M | 105 M | 72.8 M | 72.8 M | 72.8 M | 72.8 M | 129 M | 129 M | 129 M | 129 M | -77.1 M | -77.1 M | -77.1 M | -77.1 M | -44.5 M | 58.7 M | 58.7 M | 58.7 M | -23.1 M | - | - | - | -34.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency